NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

KZIA

Kazia Therapeutics Limited ADR

Jul 11 • 04:00PM ET

10.80

Dollar change +0.44
Percentage change 4.25	%

Healthcare • Biotechnology • Australia • NASD

Peers: NBIX AUPH EXEL FATE ONCT SRPT XNCR JAZZ

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-29.44	Insider Own	-	Shs Outstand	0.97M	Perf Week	60.00%
Market Cap	10.48M	Forward P/E	-	EPS next Y	-0.01	Insider Trans	-	Shs Float	-	Perf Month	105.51%
Enterprise Value	8.67M	PEG	-	EPS next Q	-	Inst Own	11.53%	Short Float	-	Perf Quarter	211.02%
Income	-18.73M	P/S	6.89	EPS this Y	-	Inst Trans	12.54%	Short Ratio	0.02	Perf Half Y	23.43%
Sales	1.52M	P/B	-	EPS next Y	-	ROA	-135.08%	Short Interest	0.02M	Perf YTD	22.03%
Book/sh	-2.44	P/C	5.51	EPS next 5Y	94.35%	ROE	-3028.18%	52W High	79.00 -86.33%	Perf Year	12.50%
Cash/sh	1.96	P/FCF	-	EPS past 3/5Y	-7.62% 11.47%	ROIC	-	52W Low	2.86 277.62%	Perf 3Y	-94.93%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-48.89% -	Gross Margin	-	Volatility	21.36% 16.69%	Perf 5Y	-94.00%
Dividend TTM	-	EV/Sales	5.70	EPS Y/Y TTM	-32.63%	Oper. Margin	-1264.44%	ATR (14)	1.21	Perf 10Y	-99.22%
Dividend Ex-Date	-	Quick Ratio	0.24	Sales Y/Y TTM	-	Profit Margin	-1232.83%	RSI (14)	74.25	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.21	EPS Q/Q	32.30%	SMA20	36.57%	Beta	2.61	Target Price	14.00
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	91.70%	Rel Volume	0.11	Prev Close	10.36
Employees	-	LT Debt/Eq	-	Earnings	-	SMA200	-5.92%	Avg Volume	1.08M	Price	10.80
IPO	Jan 06, 1999	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	119,802	Change	4.25%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-06-25	Initiated	Maxim Group	Buy	$3
Oct-14-21	Initiated	Maxim Group	Buy	$18
Jan-05-21	Initiated	H.C. Wainwright	Buy	$17

Jul-10-25 09:20AM	Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up (PR Newswire) +8.71%
Jul-09-25 02:47PM	Kazia Reports Over 50% Cancer Cell Reduction In Early Data From Breast Cancer Trial, Stock Jumps (Benzinga) +39.63%
08:00AM	Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial (PR Newswire)
Jun-11-25 08:00AM	Kazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisib's Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer (TNBC) (PR Newswire) +81.53%
Jun-05-25 08:00AM	Kazia Therapeutics Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast Cancer (PR Newswire)
08:00AM	Loading…
May-15-25 08:00AM	Kazia Therapeutics Highlights Recent Progress and Provides Business Update (PR Newswire) -6.51%
Mar-31-25 07:30AM	Kazia Therapeutics Announces Sale of Intellectual Property and Trademarks Rights for Cantrixil (PR Newswire) -11.04%
Feb-20-25 08:46AM	Kazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation to Evaluate the Therapeutic Potential of Paxalisib as a Treatment for Parkinson's Disease (PR Newswire)
Jan-31-25 07:29AM	Is Kazia Therapeutics (KZIA) One of the Best ASX Stocks to Buy According to Hedge Funds? (Insider Monkey) -16.84%
Jan-30-25 07:30AM	Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer (PR Newswire) +37.68%
Jan-27-25 08:00AM	Why Kazia Therapeutics (KZIA) Is Among the Best Australian Stocks to Buy Now? (Insider Monkey) -8.82%
Jan-14-25 04:00PM	Kazia Therapeutics Announces Closing of $2.0 Million Registered Direct Offering (PR Newswire)
Jan-11-25 10:05AM	Kazia Therapeutics to sell 1.33M ADS at $1.50 in registered direct offering (TipRanks)
Jan-10-25 09:58AM	Kazia Therapeutics Announces $2.0 Million Registered Direct Offering (PR Newswire) -6.51%
Dec-31-24 12:34PM	Why Is Brain Cancer-Focused Kazia Therapeutics Stock Trading Lower On Tuesday? (Benzinga) -42.90%
08:00AM	Loading…
08:00AM	Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA (PR Newswire)
Dec-11-24 08:00AM	Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer Symposium (PR Newswire)
Nov-04-24 07:30AM	Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme (PR Newswire) +19.20%
Oct-16-24 07:27AM	Kazia Therapeutics Adjusts ADS Ratio to Boost Nasdaq Listing (TipRanks)
Oct-15-24 07:32AM	Breast Cancer Awareness Month Sees Biotech Advancements and Worrying Trends for Young Women (PR Newswire) -18.01%
Oct-02-24 08:45AM	Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society for Radiation Oncology 66th Annual Meeting (PR Newswire)
Sep-23-24 08:30AM	Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium (PR Newswire)
Sep-12-24 07:30AM	KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER (PR Newswire) -5.25%
Jul-31-24 09:53AM	7 Top Stocks Under $10: July 2024 Edition (InvestorPlace)
07:00AM	Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making? (InvestorPlace)
Jul-25-24 06:10AM	Biotech Stock Laboratory: Try a Small Experiment With Kazia Therapeutics (InvestorPlace) +15.59%
Jul-12-24 11:24AM	Kazia Therapeutics (KZIA) Soars 490% in a Week: Here's Why (Zacks) -27.76%
10:08AM	From Pennies to Dollars: 3 Sub-$5 Stocks Set to Explode Higher (InvestorPlace)
07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
Jul-11-24 01:26PM	Silk Recalls 2024: What to Know as Plant-Based Milk Recalled Over Listeria Concerns (InvestorPlace) +85.57%
01:01PM	Loading…
01:01PM	FCEL Stock Alert: FuelCell Energy Pops on Korean Market Update (InvestorPlace)
12:51PM	JOBY Stock Pops After Completing 523-Mile eVTOL Flight (InvestorPlace)
12:31PM	KZIA Stock Alert: Kazia Continues Its Surge on Thursday With 51% Gains (InvestorPlace)
07:29AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace)
06:32AM	Kazia Therapeutics stocks soar following Phase II/III win (Clinical Trials Arena)
Jul-10-24 12:42PM	KBW Just Cut Its Price Target on SoFi (SOFI) Stock (InvestorPlace) +248.02%
12:08PM	PLUG Stock: Plug Power Shares Hydrogen Refueling Station Update (InvestorPlace)
11:57AM	Why Is Kazia Therapeutics (KZIA) Stock Up 300% Today? (InvestorPlace)
07:30AM	Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma (PR Newswire)
Jun-27-24 08:15AM	KAZIA ANNOUNCES UPCOMING DIPG DATA PRESENTATIONS AT ISPNO AND PUBLICATION IN EUROPEAN JOURNAL OF CANCER (PR Newswire) +6.37%
May-23-24 02:41PM	Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement (PR Newswire)
May-21-24 07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
May-02-24 04:22AM	Kazia concludes first stage of Phase I advanced cancer treatment trial (Clinical Trials Arena) -5.42%
May-01-24 08:45AM	KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS (PR Newswire) -10.78%
Mar-24-24 07:55AM	11 Best ASX Stocks To Buy Now (Insider Monkey)
Mar-21-24 08:52AM	Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases (PR Newswire) -8.89%
Mar-13-24 08:00AM	Kazia announces presentation of new data at AACR Annual Meeting (PR Newswire) +8.36%
Feb-21-24 07:30AM	Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint (PR Newswire) -20.61%
Jan-18-24 07:30AM	KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS (PR Newswire)
Dec-05-23 06:02PM	Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering (PR Newswire)
Dec-01-23 08:00AM	Kazia Therapeutics Announces $2 Million Registered Direct Offering (PR Newswire) -19.56%
Nov-29-23 07:01AM	KAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGY (PR Newswire) -6.34%
Nov-21-23 07:30AM	KAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING (PR Newswire) -10.59%
Nov-20-23 04:30PM	KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION (PR Newswire) -6.11%
Nov-15-23 08:30AM	KAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY ABSTRACT HIGHLIGHTING PAXALISIB IN DIFFUSE MIDLINE GLIOMA PATIENTS AHEAD OF THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING (PR Newswire)
Nov-10-23 07:01AM	KAZIA ANNOUNCES PUBLICATION IN MOLECULAR CANCER THERAPEUTICS HIGHLIGHTING PAXALISIB PRECLINICAL DATA IN MELANOMA (PR Newswire)
Nov-01-23 07:01AM	KAZIA THERAPEUTICS PROVIDES PRELIMINARY UPDATE FROM ONGOING PHASE 2 STUDY OF PAXALISIB IN PRIMARY CNS LYMPHOMA (PR Newswire)
Oct-23-23 07:01AM	KAZIA THERAPEUTICS ANNOUNCES CLINICAL DATA AT ESMO 2023 FROM ONGOING PHASE 1 EVT801 STUDY (PR Newswire) -5.29%
Oct-11-23 07:01AM	Kazia announces voluntary delisting from ASX (PR Newswire) -15.78%
Oct-05-23 07:01AM	KAZIA THERAPEUTICS ANNOUNCES PRESENTATIONS AT UPCOMING SCIENTIFIC MEETINGS (PR Newswire)
Sep-29-23 07:01AM	KAZIA THERAPEUTICS ANNOUNCES ACCEPTANCE OF LATE-BREAKING ABSTRACT AND ORAL PRESENTATION OF PNOC022 CLINICAL DATA AT 2023 SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING (PR Newswire) -5.21%
Jul-06-23 07:00AM	KAZIA'S PAXALISIB RECEIVES FAST TRACK DESIGNATION FROM FDA FOR TREATMENT OF SOLID TUMOR BRAIN METASTASES HARBORING PI3K PATHWAY MUTATIONS IN COMBINATION WITH RADIATION THERAPY (PR Newswire) -8.55%
Jun-08-23 07:00AM	KAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMA (PR Newswire)
May-25-23 07:01AM	KAZIA CEO, DR. JOHN FRIEND TO PARTICIPATE IN WHITE HOUSE CANCER MOONSHOT (PR Newswire)
Apr-14-23 07:01AM	KAZIA REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT (PR Newswire) +9.09%
Apr-04-23 07:00AM	KAZIA PRESENTS NEW DATA FOR PAXALISIB AND EVT801 AT AACR ANNUAL MEETING (PR Newswire) +6.86%
Jan-25-23 03:03PM	Trade Alert: Stephen Abolakian At Kazia Therapeutics Limited (ASX:KZA), Has Just Spent AU$1m Buying 54% More Shares (Simply Wall St.) -5.81%
Jan-18-23 11:50AM	Kazia Therapeutics CEO talks $4.5 million capital raise (News Direct) +5.28%
Jan-16-23 07:01AM	KAZIA RAISES A$4.5 MILLION TO PROGRESS R&D PROGRAMS (PR Newswire)
Dec-19-22 09:00PM	Kazia Therapeutics (KZIA): Collaboration May Expand Utility to Combo Therapies (ACCESSWIRE)
Dec-15-22 07:01AM	KAZIA LAUNCHES PRECLINICAL COLLABORATION WITH QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE AND ANNOUNCES PATENT FILING (PR Newswire)
Dec-12-22 07:01AM	KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION (PR Newswire)
Dec-01-22 07:01AM	COMPELLING PRECLINICAL DATA FOR KAZIA'S EVT801 PUBLISHED IN PEER-REVIEWED CANCER RESEARCH JOURNAL (PR Newswire) +5.20%
Nov-28-22 04:50PM	Quite a few insiders invested in Kazia Therapeutics Limited (ASX:KZA) last year which is positive news for shareholders (Simply Wall St.)
Nov-09-22 07:00AM	KAZIA TO PRESENT PAXALISIB DATA IN ADULT AND PEDIATRIC BRAIN CANCER AT SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING (PR Newswire)
Nov-02-22 07:10AM	Kazia Therapeutics (KZIA): Q123 Cash Flows in Line with Our Estimates (ACCESSWIRE) +5.68%
Oct-27-22 10:48AM	Kazia Therapeutics Reveals Paxalisib Preclinical Data In Melanoma Animal Models (Benzinga)
07:00AM	KAZIA'S PAXALISIB DEMONSTRATES POSITIVE MONOTHERAPY EFFICACY SIGNALS IN PRECLINICAL MODELS OF MELANOMA (PR Newswire)
Oct-06-22 08:00AM	PNOC CLINICAL STUDY OF KAZIA'S PAXALISIB IN CHILDHOOD BRAIN CANCER EXPANDS INTERNATIONALLY (PR Newswire) -11.48%
Sep-26-22 09:55AM	Novogen Limited (KZIA) Could Find Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Sep-09-22 08:00AM	KAZIA THERAPEUTICS TO PRESENT AT HC WAINWRIGHT 24th ANNUAL GLOBAL INVESTMENT CONFERENCE (PR Newswire)
Sep-08-22 06:00PM	KAZIA TO PRESENT FINAL DATA FROM PAXALISIB PHASE II STUDY IN GLIOBLASTOMA AT ESMO (PR Newswire)
Sep-07-22 10:35AM	Kazia Therapeutics (KZIA): Doubling Down on Clinical Development (ACCESSWIRE)
Aug-11-22 09:55AM	Here's Why Novogen Limited (KZIA) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Aug-05-22 10:00AM	Kazia Therapeutics Shares Jump On Interim Data From Paxalisib Combo Study In Brain Metastases (Benzinga)
08:40AM	KAZIA THERAPEUTICS REPORTS PROMISING INTERIM DATA FROM COMBINATION STUDY OF PAXALISIB WITH RADIOTHERAPY IN TREATMENT OF BRAIN METASTASES (PR Newswire)
Aug-01-22 07:00AM	Kazia Shares Tumble After Update From Pivotal Brain Tumor Trial (Benzinga) -47.11%
Jul-17-22 06:28PM	Kazia Therapeutics (ASX:KZA) Is In A Strong Position To Grow Its Business (Simply Wall St.)
Jul-12-22 08:15AM	KAZIA LAUNCHES NEW SCIENTIFIC ADVISORY BOARD COMPRISED OF WORLD-LEADING EXPERTS IN BRAIN CANCER (PR Newswire)
Jul-06-22 07:00AM	US FDA AWARDS RARE PEDIATRIC DISEASE DESIGNATION (RPDD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER (PR Newswire)
Jun-17-22 08:00AM	US FDA AWARDS ORPHAN DRUG DESIGNATION (ODD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER (PR Newswire)
Jun-13-22 07:00AM	POSITIVE DATA FOR PAXALISIB IN TWO CHILDHOOD BRAIN CANCERS PRESENTED AT 20TH ISPNO ANNUAL MEETING (PR Newswire) -5.47%
Jun-08-22 08:49PM	Quite a few insiders invested in Kazia Therapeutics Limited (ASX:KZA) last year which is positive news for shareholders (Simply Wall St.) +5.58%
Jun-07-22 07:00AM	PHASE II STUDY OF PAXALISIB IN BRAIN METASTASES ADVANCES TO EXPANSION STAGE IN BREAST CANCER BRAIN METASTASES COHORT (PR Newswire)
Jun-03-22 07:00AM	KAZIA PRESENTS POSITIVE FINAL DATA FROM PHASE II STUDY OF PAXALISIB IN NEWLY DIAGNOSED GLIOBLASTOMA AT ASCO CONFERENCE (PR Newswire)
May-31-22 07:00AM	GBM AGILE OPENS TO PAXALISIB IN EUROPE (PR Newswire)
May-26-22 07:50AM	Kazia Therapeutics (KZIA): Deep Dive Into Childhood Brain Cancer (ACCESSWIRE)
May-23-22 08:30AM	KAZIA THERAPEUTICS TO PRESENT AT UPCOMING INVESTOR CONFERENCES HOSTED BY HC WAINWRIGHT AND LD MICRO (PR Newswire)
May-17-22 08:00AM	KAZIA MARKS DIPG AWARENESS DAY; NEW PRECLINICAL DATA IN DIPG TO BE PRESENTED AT ISPNO CONFERENCE (PR Newswire) +8.41%
May-16-22 09:12PM	Investing in Kazia Therapeutics (ASX:KZA) three years ago would have delivered you a 69% gain (Simply Wall St.)

Kazia Therapeutics Ltd. is an oncology-focused biotechnology company, which engages in the business of pharmaceutical drug development. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KZIA

Kazia Therapeutics Limited ADR

Upgrade your FINVIZ experience